Leukemias, lymphomas, and other hematologic cancers:
Indications for: EVOMELA
High-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Adult Dosage:
Give prophylactic antiemetics. Give by IV infusion over 30mins. 100mg/m2 daily for 2 consecutive days (Days -3 and -2) prior to transplantation (Day 0). If patient weighs >130% of their ideal body weight, use adjusted ideal body weight.
Children Dosage:
Not established.
Boxed Warning:
Severe bone marrow suppression. Hypersensitivity. Leukemogenicity.
EVOMELA Warnings/Precautions:
Bone marrow suppression. Monitor CBCs, provide supportive care for infections, anemia, thrombocytopenia until adequate recovery. GI toxicity; provide supportive care. Monitor LFTs. Renal impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
EVOMELA Classification:
Alkylating agent.
EVOMELA Interactions:
Caution with cyclosporine, BCNU.
Adverse Reactions:
Decreased neutrophil, WBC, lymphocyte, and platelet counts, diarrhea, nausea, fatigue, hypokalemia, anemia, vomiting; mucositis, hypersensitivity reactions, hepatic disorders, secondary malignancies, infertility.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial (20mL)—1
